Beat­ing Mer­ck, Pfiz­er gets pri­or­i­ty re­view as the first Pre­vnar fol­low-up heads to the FDA

It won’t get quite the work-on-Thanks­giv­ing wel­come that the Covid-19 jab re­ceived, but an­oth­er Pfiz­er vac­cine is head­ed to the FDA, where it will re­ceive a speedy re­view.

Pfiz­er an­nounced Wednes­day that an ap­pli­ca­tion for its new pneu­mo­coc­cal vac­cine, 20vP­nC, has been ac­cept­ed and grant­ed pri­or­i­ty re­view at the agency, set­ting up a de­ci­sion by June of next year.

With the ac­cep­tance, Pfiz­er re­mains a step ahead of Mer­ck in the race to de­vel­op a fol­low-on to one of the Big Phar­ma’s most im­por­tant prof­it gen­er­a­tors. While most vac­cines are slim mar­gin prod­uct, Pre­vnar col­lect­ed $6 bil­lion in rev­enue last year, more than any oth­er ful­ly owned Pfiz­er prod­uct.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN